Garnett et al. (2012) tested up to 714 cell lines for their response to 138 anticancer agents including ten PI3K pathway inhibitors downstream of RTKs (http://www.cancerrxgene.org/; Release 2, July 2012), and observed that, in line with previous findings, cancer cells harboring mutations in PIK3CA and PTEN were sensitive to treatment with the AKT inhibitor VIII and MK-2206, respectively. The gene discussed is AKT1; the disease is cancer.